10-K: Vaso Corp. Reports 65% Net Income Growth, Strategic Divestment

Vaso Corporation announced its annual results for 2025, reporting a significant increase in net income driven by strategic divestments and strong professional sales services, despite an impairment charge in its IT segment.

Summary

• Total revenues increased by $2,329,000, or 2.7%, to $89,096,000 in the year ended December 31, 2025, from $86,767,000 in 2024.
• Net income increased by $618,000, or 65.0%, to $1,569,000 in 2025 from $951,000 in 2024.
• Net income per basic and diluted common share remained $0.01 for both 2025 and 2024.
• IT segment revenue decreased by $489,000, or 1.1%, to $42,465,000, primarily due to the sale of VasoHealthcare IT (VHC-IT) in November 2025, partially offset by an increase of $932,000 in managed network services revenue.
• Professional sales service segment commission revenues increased by $2,856,000, or 6.9%, to $44,191,000, driven by a higher blended commission rate and increased GEHC equipment delivery volume.
• Equipment segment revenue decreased by $38,000, or 1.5%, to $2,440,000, mainly due to a 13.3% decrease in China operations, partially offset by a 35.9% increase in US ARCS-cloud software-as-a-service revenues.
• Gross profit increased by $2,622,000, or 5.0%, to $54,672,000, with the gross margin improving to 61.4% in 2025 from 60.0% in 2024.
• Operating loss was $2,891,000 in 2025, a decrease of $3,176,000 from an operating income of $285,000 in 2024, primarily due to a $4,639,000 goodwill impairment charge in the IT segment.
• Adjusted EBITDA decreased by $2,549,000 to $(1,548,000) in 2025 from $1,001,000 in 2024.
• The company recorded an income tax benefit of $2,875,000 in 2025, compared to an expense of $326,000 in 2024, primarily due to the release of the remaining deferred tax asset valuation allowance of $3,027,000.
• Cash and cash equivalents were $35,050,000 at December 31, 2025, up from $26,271,000 in 2024.
• The GEHC Agreement, a significant revenue source, was extended through December 31, 2030.

Sentiment

Score: 4

Explanation: StockSavvy.ai views this as a mixed report. While net income improved due to tax benefits and a divestment gain, core operating performance declined significantly due to a large impairment charge and increased SG&A, indicating underlying operational challenges despite revenue growth in a key segment.

Positives

• Net income increased by 65.0% to $1,569,000 in 2025, driven by higher income tax benefit and a gain on sale of a subsidiary.
• Total revenues grew by 2.7% to $89,096,000 in 2025.
• Professional sales service segment revenue increased by 6.9% to $44,191,000, attributed to higher blended commission rates and increased GEHC equipment delivery volume.
• Gross profit increased by 5.0% to $54,672,000, with the overall gross margin improving to 61.4% in 2025.
• Managed network services revenue within the IT segment increased by $932,000.
• US operations in the equipment segment saw a 35.9% increase in ARCS-cloud software-as-a-service revenues.
• The exclusive sales representation agreement with GE HealthCare (GEHC), a significant revenue source, was extended through December 31, 2030.
• The company recorded an income tax benefit of $2,875,000 in 2025, primarily due to the release of a $3,027,000 deferred tax asset valuation allowance.
• Cash and cash equivalents increased to $35,050,000 at year-end 2025, from $26,271,000 in 2024.
• The company expects to generate sufficient cash flow from operations to satisfy its obligations for at least the next twelve months.
• No material cybersecurity incidents were experienced during fiscal year 2025.

Negatives

• Operating loss was $2,891,000 in 2025, a significant decline from an operating income of $285,000 in 2024.
• A substantial goodwill impairment charge of $4,639,000 was recorded in the NetWolves reporting unit within the IT segment.
• Adjusted EBITDA decreased by $2,549,000 to $(1,548,000) in 2025 from $1,001,000 in 2024.
• IT segment revenue decreased by 1.1% due to the sale of the VasoHealthcare IT (VHC-IT) business unit in November 2025.
• Equipment segment revenue decreased by 1.5%, with China operations experiencing a 13.3% decrease due to lower deliveries.
• Equipment segment gross profit decreased by 8.8% due to lower gross margin in US operations resulting from higher software upgrade costs.
• Operating income in the professional sales service segment decreased by 3.3% due to higher selling, general, and administrative (SG&A) costs.
• Selling, general and administrative expenses increased by $3,212,000, or 6.6%, in 2025, primarily in the professional sales service segment.
• The business combination agreement with Achari Ventures Holdings Corp. I was terminated in September 2024.
• The common stock price experienced significant volatility, with a high of $0.33 in Q1 2024 dropping to a low of $0.11 in Q3 2025.

Risks

• Substantial reliance on the GEHC agreement, which generates approximately 50% of revenue and all operating income; termination or non-extension would have a material adverse effect.
• Maintaining profitable operations is dependent on the continued GEHC Agreement, as well as attaining and maintaining profitability in the IT and equipment segments.
• Competition from other companies and technologies in all business segments could lead to existing products becoming obsolete or non-competitive.
• Data security incidents or disruptions in information technology systems could damage the business, especially with increased work-from-home arrangements.
• Dependence on a limited number of key management and technical personnel; the loss of one or more key employees may harm the business.
• Inability to receive necessary clearances or approvals from the US FDA or foreign authorities for medical devices could hinder the ability to market and sell certain products.
• Failure to comply with extensive governmental regulations across business lines (telecommunications, medical devices, healthcare fraud/abuse) could lead to significant costs or operational cessation.
• Risks associated with foreign operations, including currency exchange rates, different legal and regulatory environments, political and economic risks, and unclear tax laws in China.
• Dependence on several suppliers for certain products, including GEHC equipment, which could be negatively impacted by supply chain issues, such as the availability of computer chips.
• Inadequate intellectual property protection, potential patent violations, costly litigation, or infringement of patents held by others.
• Growth could suffer if the IT and healthcare markets decline, do not grow as anticipated, or experience cyclicality.
• Difficulty in predicting and managing technological change in the IT and medical device fields, potentially leading to unforeseen problems or product abandonment.
• Exposure to product liability claims and product recalls, which may not be fully covered by insurance and could damage the company's reputation.
• The common stock is subject to price volatility due to various factors beyond the company's control, including operating results, economic conditions, and competitive actions.
• Anti-takeover provisions in the Articles of Incorporation may deter or make more difficult a takeover, even if shareholders may desire it.
• Cybersecurity risk cannot be eliminated, and future incidents may occur despite robust programs.
• Uncertainty in future order cancellations for commission adjustments, as historical rates may not predict future activity.
• Subjectivity in the 'more likely than not' standard for deferred tax asset realization, which relies on accurate projection of taxable income.
• Chinese subsidiaries' ability to pay dividends is subject to limitations, including statutory reserves and potential withholding taxes.
• Utilization of net operating loss carryforwards could be restricted by Section 382 of the Internal Revenue Code if an ownership change occurs.

Future Outlook

The company plans to continue effectively controlling operating costs in the current inflationary environment and expand its product and service offerings. It aims to maintain and improve business performance in the professional sales service segment by increasing market penetration of the GEHC product portfolio and seeking opportunities to represent other medical device vendors. The equipment business will focus on increasing efficiency, transforming operations, and exploring new revenue models. The company will also continue to seek accretive partnership opportunities, evaluate and optimize its business portfolio, and explore options in capital markets for stock liquidity. Management expects to generate sufficient cash flow from operations to satisfy its obligations for at least the next twelve months.

Management Comments

• We believe that our employee relations are good.
• We believe that our current facilities are adequate for foreseeable current and future needs.
• We believe our manufacturing capacity and warehouse facility are adequate to meet the current and immediately foreseeable future demand for the production of our medical devices.
• We believe our suppliers of the other medical devices we distribute or represent are capable of meeting our demand for the foreseeable future.
• While we believe we are in compliance with laws and regulations in jurisdictions where we do business, we continue to monitor and assess our compliance.
• The Company believes that the outcome of all such pending legal proceedings in the aggregate is unlikely to have a material adverse effect on the business or consolidated financial condition of the Company.
• The Company expects to generate sufficient cash flow from operations to satisfy its obligations at least for the next twelve months.
• We believe that inflation and changing prices over the past two years have not had a significant impact on our revenue or on our results of operations.
• Management is currently unaware of any issues under review that could result in significant payments, accruals or material deviations from its position.

Industry Context

StockSavvy.ai notes that Vaso Corporation's strategic divestment of its healthcare IT services aligns with a broader industry trend of companies streamlining operations to focus on core competencies, especially in the competitive healthcare IT and medical device sectors. The continued strong performance in professional sales services for GEHC diagnostic imaging equipment highlights the resilience of established partnerships in capital equipment sales, while the goodwill impairment in the IT segment underscores the challenges of rapid technological shifts and market consolidation in that space. The company's focus on expanding SaaS offerings in its equipment segment reflects the growing demand for recurring revenue models and cloud-based solutions in healthcare.

Comparison to Industry Standards

• NA

Management Changes

Corporate Governance

Legal Proceedings

• The company is currently, and has been in the past, a party to various routine legal proceedings, primarily employee-related matters, incident to the ordinary course of business.
• The company believes that the outcome of all such pending legal proceedings in the aggregate is unlikely to have a material adverse effect on the business or consolidated financial condition of the Company.

Related Party Transactions

• No transactions were disclosed where the amount involved exceeded the lesser of $120,000 or 1% of the company's average total assets, and any Director, Director nominee, executive officer, or their immediate family members had a direct or indirect material interest reportable under applicable SEC rules, nor are any such transactions currently proposed.

Stakeholder Impact

• Shareholders: Net income growth and increased cash are positive, but the operating loss and goodwill impairment are concerning. Stock price volatility is a noted risk, and no dividends are expected.
• Employees: The company believes employee relations are good, and executive compensation details are provided.
• Customers: Continued expansion of product and service offerings, and maintaining the GEHC partnership, aim to benefit customers.
• Suppliers: Dependence on suppliers, including GEHC, and potential supply chain issues (e.g., computer chips) could impact operations.
• Creditors: Compliance with financial covenants on the revolving credit agreement indicates good standing, and sufficient cash flow is expected for the next 12 months.

Next Steps

• Continue to effectively control operating costs in the current inflationary environment.
• Expand product and service offerings.
• Maintain and improve business performance in the professional sales service segment by increasing market penetration of the GEHC product portfolio.
• Seek opportunities in medical device sales to represent other vendors.
• Maintain and grow the equipment business by increasing efficiency and continuing to transform operations.
• Explore new revenue models in the equipment business.
• Continue to seek accretive partnership opportunities.
• Continue to evaluate and optimize the business portfolio.
• Explore options in capital markets for liquidity of stock.
• The EECP Global Management Service Agreement will automatically renew for another year after April 1, 2026.

Key Dates

Recommendation

While Vaso Corporation achieved net income growth and increased cash, primarily due to a one-time divestment gain and tax benefits, its core operating performance deteriorated significantly, marked by a substantial goodwill impairment and a shift to an operating loss. The extension of the critical GEHC agreement provides stability, but the underlying operational challenges and stock price volatility warrant a cautious "hold" stance for investors, awaiting clearer signs of sustained operational profitability beyond non-recurring items.

Keywords

Healthcare IT, Managed Network Services, Medical Devices, Diagnostic Imaging, GE HealthCare, EECP, Cardiovascular, SaaS, Telecommunications, Cybersecurity, SEC Filing, Annual Report, Financial Results, Corporate Governance, Risk Factors, Vaso Corporation